Actively Recruiting
Effect of L-Carnitine Supplementation in Preterm Neonates Suffering From Respiratory Distress Syndrome (RDS)
Led by Muhammad Aamir Latif · Updated on 2026-02-27
160
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the effects of L-carnitine supplementation in preterm newborns with Respiratory Distress Syndrome (RDS). The trial aims to clarify how L-carnitine influences short-term outcomes like weight gain, discharge rates, and survival, especially given conflicting data and lack of evidence among the local population. This research focuses on neonates who may be deficient in L-carnitine and seeks to address their metabolic needs. Participants are randomly assigned to one of two groups. One group receives L-carnitine at 30 mg/kg/day alongside a standard care regimen consisting of 100 mg phospholipids per kg of birth weight, divided into four doses. The other group receives only the standard care regimen without L-carnitine. Both treatments are given during their stay in the neonatal intensive care unit. During the study, the babies' health is closely monitored, including their weight changes and survival status over 30 days. Researchers will assess how L-carnitine supplementation affects these outcomes compared to standard care alone. The study is designed to provide evidence on the safety and potential benefits of adding L-carnitine for managing preterm neonates with RDS, with participation lasting at least 30 days post-treatment.
CONDITIONS
Brief Title
Effect of L-Carnitine Supplementation in Preterm Neonates
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Preterm neonates
- Any gender
- Diagnosed with Respiratory Distress Syndrome (RDS)
- Admitted to the neonatal intensive care unit (NICU) within 24 hours of birth
You will not qualify if you...
- Neonates with gastrointestinal tract anomalies
- Neonates with confirmed or suspected sepsis at enrollment
- Neonates expected to survive less than 48 hours as judged by a neonatologist
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 30 days
Participants receive either L-carnitine supplementation along with standard care or standard care alone to manage Respiratory Distress Syndrome.
Daily treatment visits during hospital stay
Trial Site Locations
Total: 1 location
1
Recep Tayyip Erdogan Hospital/Indus Hospital & Health Network
Muzaffargarh, Punjab Province, Pakistan, 32400
Actively Recruiting
Research Team
M
Muhammad Sarfraz, FCPS
A
Athar Razzaq, FCPS
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here